Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

11.04.24 23:50 Uhr

Werte in diesem Artikel
Aktien

121,00 EUR 0,00 EUR 0,00%

167,60 EUR -2,25 EUR -1,32%

Indizes

PKT PKT

PKT PKT

1.615,0 PKT 1,5 PKT 0,09%

18.693,4 PKT 2,1 PKT 0,01%

7.195,0 PKT -0,7 PKT -0,01%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

189,8 PKT 0,7 PKT 0,38%

39.069,6 PKT 4,3 PKT 0,01%

521,8 PKT -0,2 PKT -0,04%

9.961,4 PKT 0,9 PKT 0,01%

18.700,0 PKT 115,0 PKT 0,62%

18.679,1 PKT 65,3 PKT 0,35%

15.248,7 PKT -196,7 PKT -1,27%

7.362,9 PKT 0,2 PKT 0,00%

16.939,8 PKT 9,0 PKT 0,05%

2.533,1 PKT 17,9 PKT 0,71%

5.304,7 PKT 36,9 PKT 0,70%

18.701,0 PKT 107,4 PKT 0,58%

Merck (MRK) closed the most recent trading day at $126.15, moving -0.47% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq added 1.68%.The pharmaceutical company's stock has climbed by 3.76% in the past month, exceeding the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8%.Investors will be eagerly watching for the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 25, 2024. It is anticipated that the company will report an EPS of $2.06, marking a 47.14% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $15.32 billion, up 5.75% from the prior-year quarter.For the full year, the Zacks Consensus Estimates are projecting earnings of $8.58 per share and revenue of $64.06 billion, which would represent changes of +468.21% and +6.56%, respectively, from the prior year.Investors should also take note of any recent adjustments to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.02% lower. Right now, Merck possesses a Zacks Rank of #3 (Hold).In terms of valuation, Merck is presently being traded at a Forward P/E ratio of 14.78. This expresses a premium compared to the average Forward P/E of 14.1 of its industry.We can also see that MRK currently has a PEG ratio of 0.5. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.71 based on yesterday's closing prices.The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 223, positioning it in the bottom 12% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Merck

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Merck

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Merck KGaA

Analysen zu Merck KGaA

DatumRatingAnalyst
23.05.2024Merck BuyUBS AG
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
DatumRatingAnalyst
23.05.2024Merck BuyUBS AG
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
DatumRatingAnalyst
06.12.2023Merck HaltenDZ BANK
27.11.2023Merck HaltenDZ BANK
27.04.2023Merck HaltenDZ BANK
10.11.2022Merck NeutralUBS AG
05.08.2022Merck HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"